PLoS ONE (Jan 2021)

Mortality and evolution between community and hospital-acquired COVID-AKI.

  • Jonathan S Chávez-Íñiguez,
  • José H Cano-Cervantes,
  • Pablo Maggiani-Aguilera,
  • Natashia Lavelle-Góngora,
  • Josué Marcial-Meza,
  • Estefanía P Camacho-Murillo,
  • Cynthia Moreno-González,
  • Jarumi A Tanaka-Gutiérrez,
  • Ana P Villa Zaragoza,
  • Karla E Rincón-Souza,
  • Sandra Muñoz-López,
  • Olivia Montoya-Montoya,
  • Guillermo Navarro-Blackaller,
  • Aczel Sánchez-Cedillo,
  • Luis E Morales-Buenrostro,
  • Guillermo García-García

DOI
https://doi.org/10.1371/journal.pone.0257619
Journal volume & issue
Vol. 16, no. 11
p. e0257619

Abstract

Read online

BackgroundAcute kidney injury (AKI) is associated with poor outcomes in COVID patients. Differences between hospital-acquired (HA-AKI) and community-acquired AKI (CA-AKI) are not well established.MethodsProspective, observational cohort study. We included 877 patients hospitalized with COVID diagnosis at two third-level hospitals in Mexico. Primary outcome was all-cause mortality at 28 days compared between COVID patients with CA-AKI and HA-AKI. Secondary outcomes included the need for KRT, and risk factors associated with the development of CA-AKI and HA-AKI.ResultsA total of 377 patients (33.7%) developed AKI. CA-AKI occurred in 202 patients (59.9%) and HA-AKI occurred in 135 (40.1%). Patients with CA-AKI had more significant comorbidities, including diabetes (52.4% vs 38.5%), hypertension (58.4% vs 39.2%), CKD (30.1% vs 14.8%), and COPD (5.9% vs 1.4%), than those with HA-AKI. Patients' survival without AKI was 87.1%, with CA-AKI it was 75.4%, and with HA-AKI it was 69.6%, log-rank test p 60 years (OR 1.12, 95% CI 1.06-1.18, p ConclusionsWe found that COVID patients who are complicated by CA-AKI have more comorbidities and worse biochemical parameters at the time of hospitalization than HA-AKI patients, but despite these differences, their probability of dying is similar.